{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:06:03Z","timestamp":1787504763091,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors (TKIs) are essential anticancer agents associated with substantial nephrotoxic potential. Although TKI-induced renal injury is increasingly recognized, comprehensive histopathological characterization remains limited due to insufficient renal biopsy data. This study characterizes the clinicopathological spectrum and outcomes of biopsy-proven TKI nephrotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 21 patients with biopsy-proven TKI-associated renal injury identified between 2015 and 2025. Demographic characteristics, renal function indices, oncological profiles and histopathological features were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 16 patients with solid tumors and 5 with hematologic malignancies exposed to four major TKI classes: vascular endothelial growth factor receptor, platelet-derived growth factor receptor, human epidermal growth factor receptor and Bruton\u2019s tyrosine kinase TKIs. The median time from TKI initiation to symptom onset was 9.5\u00a0months. Clinical manifestations included proteinuria (95%), edema (52%) and new-onset\/worsened hypertension (47%). At biopsy, median serum creatinine was 1.07\u00a0mg\/dL (94.6\u00a0\u00b5mol\/L) and proteinuria was 1.83\u00a0g\/day. Histopathological analysis demonstrated thrombotic microangiopathy (TMA)-like lesions in 17 of 21 cases (80%), with concurrent immunoglobulin A nephropathy in 3 cases and focal segmental glomerulosclerosis in 3 cases. Among 18 patients with available follow-up data, 14 discontinued their initial TKI therapy, with 5 transitioning to alternative TKIs. Treatment strategies included angiotensin-converting enzyme inhibitor\/angiotensin-receptor blocker monotherapy (n\u00a0=\u00a013) and combination therapy with corticosteroids\/immunosuppressants (n\u00a0=\u00a05). During a median follow-up period of 9.5\u00a0months, complete and partial proteinuria remission occurred in five cases each. Four patients died due to cancer progression, while renal function remained stable in the remaining patients without progression to end-stage renal disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TKI-induced renal injury characteristically presents with edema, hypertension and significant proteinuria, with renal-limited TMA as the predominant histopathological finding. Timely recognition and prompt discontinuation of the offending TKI, coupled with appropriate supportive nephroprotective management, generally yield favorable long-term renal outcomes with preservation of kidney function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf394","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:08:47Z","timestamp":1765544927000},"source":"Crossref","is-referenced-by-count":6,"title":["Biopsy-proven tyrosine kinase inhibitor\u2013associated renal injury: a case series"],"prefix":"10.1093","volume":"19","author":[{"given":"Jingying","family":"Lian","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoshan","family":"Liang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dacheng","family":"Chen","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Zhong","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3816-5164","authenticated-orcid":false,"given":"Caihong","family":"Zeng","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"2026011003565743200_bib1","doi-asserted-by":"publisher","first-page":"e90135","DOI":"10.1371\/journal.pone.0090135","article-title":"Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"2026011003565743200_bib2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/17512433.2020.1734450","article-title":"Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Exp Rev Clin Pharmacol"},{"key":"2026011003565743200_bib3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2026011003565743200_bib4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026011003565743200_bib5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"2026011003565743200_bib6","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026011003565743200_bib7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00002018-199410020-00001","article-title":"Harmonisation in pharmacovigilance: drug safety","volume-title":"Drug Saf","author":"Edwards","year":"1994"},{"key":"2026011003565743200_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026011003565743200_bib9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/6927639","article-title":"A case of lenvatinib-induced focal segmental glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer","volume":"2018","author":"Fleming","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"2026011003565743200_bib10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12882-018-1074-3","article-title":"Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report","volume":"19","author":"Furuto","year":"2018","journal-title":"BMC Nephrol"},{"key":"2026011003565743200_bib11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00428-021-03114-5","article-title":"Lenvatinib-related renal microangiopathy: a case series","volume":"480","author":"Delsante","year":"2022","journal-title":"Virchows Arch"},{"key":"2026011003565743200_bib12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17425255.2018.1461839","article-title":"Lenvatinib-induced renal failure: two first-time case reports and review of literature","volume":"14","author":"Cavalieri","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026011003565743200_bib13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1159\/000494080","article-title":"Thrombotic microangiopathy with severe proteinuria induced by Lenvatinib for radioactive iodine-refractory papillary thyroid carcinoma","volume":"11","author":"Hyogo","year":"2018","journal-title":"Case Rep Oncol"},{"key":"2026011003565743200_bib14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12882-021-02656-9","article-title":"Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures","volume":"23","author":"Yin","year":"2022","journal-title":"BMC Nephrol"},{"key":"2026011003565743200_bib15","first-page":"428","article-title":"Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction","volume":"75","author":"Muller-Hansma","year":"2017","journal-title":"Neth J Med"},{"key":"2026011003565743200_bib16","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2215\/CJN.0000000000000219","article-title":"Patient-specific pharmacokinetics and dasatinib nephrotoxicity","volume":"18","author":"Adegbite","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026011003565743200_bib17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int"},{"key":"2026011003565743200_bib18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/cells10040869","article-title":"Abnormal crosstalk between endothelial cells and podocytes mediates tyrosine kinase inhibitor (TKI)-induced nephrotoxicity","volume":"10","author":"Gu","year":"2021","journal-title":"Cells"},{"key":"2026011003565743200_bib19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2026011003565743200_bib20","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.3390\/cancers13235907","article-title":"Renal safety profile of EGFR targeted therapies: a study from VigiBase\u00ae the WHO Global Database of Individual Case Safety Reports","volume":"13","author":"Crosnier","year":"2021","journal-title":"Cancers"},{"key":"2026011003565743200_bib21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1078-0432.CCR-09-1486","article-title":"Antitumor activity of targeting src kinases in endothelial and myeloid cell compartments of the tumor microenvironment","volume":"16","author":"Liang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2026011003565743200_bib22","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1182\/blood-2007-10-116590","article-title":"Validation of beta and c-Src tyrosine kinases as tumor\/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib","volume":"112","author":"Coluccia","year":"2008","journal-title":"Blood"},{"key":"2026011003565743200_bib23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","article-title":"Bevacizumab-associated glomerular microangiopathy","volume":"32","author":"Person","year":"2019","journal-title":"Mod Pathol"},{"key":"2026011003565743200_bib24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/ndt\/12.3.474","article-title":"Von Willebrand factor abnormalities in IgA nephropathy","volume":"12","author":"Bertaglia","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"2026011003565743200_bib25","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1053\/j.ajkd.2004.12.017","article-title":"Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?","volume-title":"Am J Kidney Dis","author":"Aly","year":"2005"},{"key":"2026011003565743200_bib26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI86418","article-title":"VEGF regulates local inhibitory complement proteins in the eye and kidney","volume":"127","author":"Keir","year":"2016","journal-title":"J Clin Invest"},{"key":"2026011003565743200_bib27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1681\/ASN.2014121165","article-title":"ADAMTS13 endopeptidase protects against vascular endothelial growth factor inhibitor\u2013induced thrombotic microangiopathy","volume":"27","author":"Erpenbeck","year":"2016","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf394\/65876725\/sfaf394.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/1\/sfaf394\/65876725\/sfaf394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/1\/sfaf394\/65876725\/sfaf394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:57:05Z","timestamp":1768035425000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf394\/8379436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf394","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,13]]},"article-number":"sfaf394"}}